Poor
Mostly Misaligned
Patient Risk:
Moderate
Summary
Claims about liver injury being caused by Lipitor and that liver enzyme elevations occur are partially supported, but the response provides specific numeric threshold ranges and diagnostic implications for ALT/AST/ALP (and “liver failure” cutoffs) that are not supported by the provided FDA label excerpts. Overall, substantial portions are unsupported.
Category Scores
Accurate Statements
Lipitor (atorvastatin) can cause liver damage.
Label excerpt 5.2 states statins are associated with biochemical abnormalities of liver function and that LIPITOR therapy has been associated with liver function abnormalities.
Elevated liver enzyme levels ... can indicate Lipitor side effects, particularly liver damage.
Label excerpt 5.2 indicates statins are associated with biochemical abnormalities of liver function; additionally, LIPITOR adverse reactions include alanine aminotransferase increase and hepatic enzyme increase (Section 6).
Liver enzyme elevations are a common side effect of statins, including Lipitor.
Label excerpt 6 lists alanine aminotransferase increase (0.4%) and hepatic enzyme increase (0.4%) as adverse reactions leading to discontinuation; the label also states statins have been associated with biochemical abnormalities of liver function (Section 5.2). Note: label excerpts provided do not support the word “common” as used in the claim.
Unsupported Statements
Rare cases of liver failure have been reported in patients taking Lipitor.
The provided label excerpts (including 4 Contraindications, 5 Warnings/Precautions Liver Dysfunction, and 6 Adverse Reactions) do not mention liver failure or rare reports of liver failure.
ALT levels of 40–100 U/L may indicate liver damage or inflammation.
No numeric ALT/AST/ALP threshold ranges are provided in the supplied label excerpts.
ALT levels of 100–200 U/L may indicate liver damage or inflammation.
No numeric ALT/AST/ALP threshold ranges or interpretive cutoffs are provided in the supplied label excerpts.
ALT levels greater than 200 U/L may indicate liver failure.
The supplied label excerpts do not define ALT thresholds for liver failure.
AST levels of 40–100 U/L may indicate liver damage or inflammation.
No numeric AST threshold ranges or interpretive cutoffs are provided in the supplied label excerpts.
AST levels of 100–200 U/L may indicate liver damage or inflammation.
No numeric AST threshold ranges or interpretive cutoffs are provided in the supplied label excerpts.
AST levels greater than 200 U/L may indicate liver failure.
The supplied label excerpts do not define AST thresholds for liver failure.
ALP levels of 120–300 U/L may indicate bile duct damage or blockage.
The supplied label excerpts do not provide ALP threshold ranges or interpretive linkage to bile duct damage/blockage.
ALP levels of 300–600 U/L may indicate bile duct damage or blockage.
The supplied label excerpts do not provide ALP threshold ranges or interpretive linkage to bile duct damage/blockage.
ALP levels greater than 600 U/L may indicate bile duct failure.
The supplied label excerpts do not provide ALP threshold ranges or interpretive linkage to bile duct failure.
Contradictions
Important Omissions
The label excerpted threshold for concern is defined as persistent elevations (>3 times ULN occurring on 2 or more occasions), but the response instead uses numeric ranges (e.g., ALT >200 U/L) as diagnostic thresholds.
Importance:
Moderate
Label-recommended monitoring includes performing liver function tests prior to and at 12 weeks following initiation and any dose elevation, and periodically thereafter; the response does not mention this monitoring guidance.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Unsupported numeric laboratory cutoffs and linking them to specific outcomes (liver failure, bile duct failure) are not provided in the supplied label excerpts and could lead to inaccurate interpretation of labs relative to on-label guidance.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Mostly Misaligned
Primary Issue
The response introduces specific ALT/AST/ALP numeric ranges and diagnostic implications (including liver failure/bile duct failure) that are not supported by the provided FDA label excerpts.
Suggested Improvement
Remove or replace numeric threshold ranges with the label excerpted criterion for persistent transaminase elevations (>3 times ULN on 2+ occasions) and include the label-recommended liver function test monitoring schedule (baseline, at 12 weeks after initiation and after dose increases, and periodically thereafter).